Glutamate receptor mGlu2 and mGlu3 knockout striata are dopamine supersensitive, with elevated D2(High) receptors and marked supersensitivity to the dopamine agonist (+)PHNO.
The finding that the mGlu2/3 metabotropic glutamate receptor agonist, LY404039, improves clinical symptoms in schizophrenia warrants a search for a possible interaction between mGlu2/3 receptors and dopamine D2 receptors. Here, this topic is examined in striatal tissue of mice lacking either mGlu2 or mGlu3 receptor. Such mice are known to be behaviorally supersensitive to dopamine receptor agonists. Therefore, to determine the basis of this dopamine supersensitivity, the proportion of dopamine D2(High) receptors was measured in the striata of mGlu2 and mGlu3 receptor knockout mice. The proportion of D2(High) receptors was found to be elevated by 220% in the striata of both knockouts. To measure the functional dopamine supersensitivity, the D2 agonist (+)PHNO was used to stimulate the incorporation of GTP-gamma-S in the striatal homogenates in the presence of drugs that blocked the dopamine D1, D3, and D5 receptors. Compared with control striata, the mGlu2 receptor knockout tissues were 67-fold more sensitive to (+)PHNO, while the mGlu3 receptor knockout tissues were 17-fold more sensitive. These data suggest that group II mGlu receptors-mGlu2 receptors in particular-may normally regulate D2 receptors by reducing the proportion of high-affinity D2 receptors in membranes. Such regulation may contribute to the antipsychotic action of mGlu2/3 receptor agonists.
Seeman
Philip
P
Department of Pharmacology, Medical Science Building, University of Toronto, 1 King's College Circle, Toronto, Ontario, Canada. philip.seeman@utoronto.ca
Battaglia
Giuseppe
G
Corti
Corrado
C
Corsi
Mauro
M
Bruno
Valeria
V
D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D003342:Corpus Striatum / Q000187:drug effects*; D004294:Domperidone / Q000493:pharmacokinetics; D004298:Dopamine / Q000494:pharmacology*; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000494:pharmacology; D051379:Mice; D018345:Mice, Knockout; D010078:Oxazines / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects; D018091:Receptors, AMPA / Q000172:deficiency*; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D018094:Receptors, Metabotropic Glutamate / Q000172:deficiency*; D010837:Vitamin K 1 / Q000031:analogs & derivatives* / Q000494:pharmacology
C510195:2-phytyl-1,4-naphthoquinone; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D010078:Oxazines; D018091:Receptors, AMPA; D017448:Receptors, Dopamine D2; D018094:Receptors, Metabotropic Glutamate; C104723:glutamate receptor ionotropic, AMPA 3; C108822:metabotropic glutamate receptor 2; C042631:naxagolide; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D004294:Domperidone; D010837:Vitamin K 1; D004298:Dopamine